Bin Tean Teh

List of Publications by Year
in descending order

292 papers	28,679 citations	4370 86 h-index	6113 159 g-index
306 all docs	306 docs citations	306 times ranked	35895 citing authors

#	Article	IF	Citations
1	Patterns of somatic mutation in human cancer genomes. Nature, 2007, 446, 153-158.	13.7	2,802
2	Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature, 2011, 469, 539-542.	13.7	1,127
3	Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature, 2010, 463, 360-363.	13.7	1,062
4	Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics, 2009, 41, 521-523.	9.4	734
5	HRPT2, encoding parafibromin, is mutated in hyperparathyroidismâ€“jaw tumor syndrome. Nature Genetics, 2002, 32, 676-680.	9.4	686
6	Signatures of mutation and selection in the cancer genome. Nature, 2010, 463, 893-898.	13.7	661
7	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	7.7	637
8	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nature Genetics, 2012, 44, 570-574.	9.4	560
9	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, 94-98.	13.7	466
10	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 2014, 123, 2915-2923.	0.6	435
11	Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer. Cancer Research, 2005, 65, 7591-7595.	0.4	429
12	Exome sequencing identifies distinct mutational patterns in liver flukeâ€“related and non-infection-related bile duct cancers. Nature Genetics, 2013, 45, 1474-1478.	9.4	426
13	Exome sequencing of liver flukeâ€“associated cholangiocarcinoma. Nature Genetics, 2012, 44, 690-693.	9.4	412
14	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. Cancer Research, 2010, 70, 1063-1071.	0.4	394
15	Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. Gastroenterology, 2013, 145, 554-565.	0.6	381
16	An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma. Cancer Cell, 2011, 20, 511-523.	7.7	347
17	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	2.8	318
18	Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Science Translational Medicine, 2017, 9, .	5.8	272

#	Article	IF	Citations
19	Cholangiocarcinoma. Nature Reviews Disease Primers, 2021, 7, 65.	18.1	270
20	Preparing the â€œSoilâ€ The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells. Cancer Research, 2006, 66, 10365-10376.	0.4	262
21	Janus Kinase 3â€“Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discovery, 2012, 2, 591-597.	7.7	236
22	Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool. Science Translational Medicine, 2013, 5, 197ra101.	5.8	233
23	Renal Translocation Carcinomas. American Journal of Surgical Pathology, 2008, 32, 656-670.	2.1	232
24	VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. Molecular and Cellular Biology, 2007, 27, 157-169.	1.1	230
25	A Molecular Classification of Papillary Renal Cell Carcinoma. Cancer Research, 2005, 65, 5628-5637.	0.4	226
26	Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma. Clinical Cancer Research, 2004, 10, 6629-6637.	3.2	223
27	Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis. JAMA - Journal of the American Medical Association, 2005, 294, 2465.	3.8	218
28	Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma. Cancer Research, 2010, 70, 1053-1062.	0.4	203
29	Birt-Hogg-DubÃ© syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene, 2001, 20, 5239-5242.	2.6	199
30	Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo. Cancer Research, 2008, 68, 81-88.	0.4	194
31	Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene, 2003, 22, 6810-6818.	2.6	192
32	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood, 2019, 133, 1664-1676.	0.6	184
33	Thymic Carcinoids in Multiple Endocrine Neoplasia Type 1. Annals of Surgery, 1998, 228, 99-105.	2.1	184
34	Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell, 2019, 35, 932-947.e8.	7.7	182
35	Regulation of endocytosis via the oxygen-sensing pathway. Nature Medicine, 2009, 15, 319-324.	15.2	178
36	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell, 2018, 33, 137-150.e5.	7.7	175

#	Article	IF	Citations
37	Glypican 3: A Novel Marker in Testicular Germ Cell Tumors. American Journal of Surgical Pathology, 2006, 30, 1570-1575.	2.1	174
38	Abscisic acid perception and signaling: structural mechanisms and applications. Acta Pharmacologica Sinica, 2014, 35, 567-584.	2.8	174
39	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nature Genetics, 2014, 46, 877-880.	9.4	172
40	Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nature Medicine, 2016, 22, 666-671.	15.2	169
41	Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2004, 28, 69-76.	2.1	168
42	Genomic landscapes of breast fibroepithelial tumors. Nature Genetics, 2015, 47, 1341-1345.	9.4	167
43	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Science Translational Medicine, 2017, 9, .	5.8	165
44	Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer. Science Translational Medicine, 2012, 4, 156ra140.	5.8	163
45	Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study. Molecular Cancer Therapeutics, 2010, 9, 1525-1535.	1.9	160
46	Tubulocystic Carcinoma of the Kidney. American Journal of Surgical Pathology, 2008, 32, 177-187.	2.1	156
47	The draft genome of tropical fruit durian (Durio zibethinus). Nature Genetics, 2017, 49, 1633-1641.	9.4	150
48	The Opisthorchis viverrini genome provides insights into life in the bile duct. Nature Communications, 2014, 5, 4378.	5.8	144
49	Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma. Cancer Research, 2007, 67, 3171-3176.	0.4	141
50	MicroRNA profiling of human kidney cancer subtypes. International Journal of Oncology, 2009, 35, 109-14.	1.4	135
51	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	6.0	134
52	Characterization of the mouse Men1 gene and its expression during development. Oncogene, 1998, 17, 2485-2493.	2.6	133
53	Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis. Cancer Research, 2011, 71, 3162-3172.	0.4	133
54	Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia. PLoS ONE, 2008, 3, e3581.	1.1	131

#	Article	IF	Citations
55	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology, 2016, 151, 637-650.e10.	0.6	127
56	Functional Importance of Dicer Protein in the Adaptive Cellular Response to Hypoxia. Journal of Biological Chemistry, 2012, 287, 29003-29020.	1.6	126
57	In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Research, 2018, 28, 654-665.	2.4	126
58	Cystic Renal Neoplasia Following Conditional Inactivation of Apc in Mouse Renal Tubular Epithelium. Journal of Biological Chemistry, 2005, 280, 3938-3945.	1.6	124
59	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nature Communications, 2016, 7, 12983.	5.8	123
60	Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein. Journal of Biological Chemistry, 2005, 280, 28507-28518.	1.6	122
61	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 434-441.	1.8	120
62	Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factorâ€“mediated upregulation of caveolin-1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4892-4897.	3.3	120
63	Clinicopathologic Studies of Thymic Carcinoids in Multiple Endocrine Neoplasia Type 1. Medicine (United States), 1997, 76, 21-29.	0.4	119
64	Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma. Journal of Urology, 2010, 184, 859-864.	0.2	118
65	As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelialâ€“mesenchymal transition and activation of AKT signaling. Carcinogenesis, 2012, 33, 1302-1309.	1.3	118
66	Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes. Clinical Cancer Research, 2014, 20, 4129-4140.	3.2	117
67	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Journal of Medical Genetics, 2011, 48, 226-234.	1.5	116
68	Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biology, 2012, 13, R115.	13.9	116
69	MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Scientific Reports, 2015, 5, 13321.	1.6	113
70	Comparative Genomic Hybridization Reveals Frequent Losses of Chromosomes 1p and 3q in Pheochromocytomas and Abdominal Paragangliomas, Suggesting a Common Genetic Etiology. American Journal of Pathology, 2000, 156, 651-659.	1.9	111
71	VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1284-1305.	7.7	111
72	The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell, 2003, 4, 405-413.	7.7	102

#	Article	IF	Citations
73	Gene expression profiling of renal medullary carcinoma. Cancer, 2004, 100, 976-985.	2.0	101
74	Robust Classification of Renal Cell Carcinoma Based on Gene Expression Data and Predicted Cytogenetic Profiles. Cancer Research, 2004, 64, 4117-4121.	0.4	99
75	Parafibromin, a Component of the Human PAF Complex, Regulates Growth Factors and Is Required for Embryonic Development and Survival in Adult Mice. Molecular and Cellular Biology, 2008, 28, 2930-2940.	1.1	97
76	A Family with Isolated Hyperparathyroidism Segregating a Missense MEN1 Mutation and Showing Loss of the Wild-Type Alleles in the Parathyroid Tumors. American Journal of Human Genetics, 1998, 63, 1544-1549.	2.6	96
77	A Genotypic and Histopathological Study of a Large Dutch Kindred with Hyperparathyroidism-Jaw Tumor Syndrome1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1449-1454.	1.8	96
78	Gene Expression of Parathyroid Tumors. Cancer Research, 2004, 64, 7405-7411.	0.4	96
79	Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer, 2009, 115, 2282-2289.	2.0	96
80	Inactivation of BHD in sporadic renal tumors. Cancer Research, 2003, 63, 4583-7.	0.4	96
81	HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncology, 2006, 42, 735-739.	0.8	95
82	C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Human Pathology, 2005, 36, 262-268.	1.1	94
83	Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis. PLoS ONE, 2014, 9, e104158.	1.1	94
84	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine, 2016, 8, 195-202.	2.7	94
85	Human Kidney Injury Molecule-1 (hKIM-1): A Useful Immunohistochemical Marker for Diagnosing Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma. American Journal of Surgical Pathology, 2007, 31, 371-381.	2.1	90
86	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Research, 2017, 27, 1475-1486.	2.4	90
87	Integrated epigenomics identifiesBMP4as a modulator of cisplatin sensitivity in gastric cancer. Gut, 2013, 62, 22-33.	6.1	88
88	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1439-1444.	3.3	87
89	Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Medicine, 2015, 7, 38.	3.6	87
90	Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer, 2010, 10, 196.	1.1	86

#	Article	IF	Citations
91	Whole-Exome Sequencing Studies of Parathyroid Carcinomas Reveal NovelPRUNE2Mutations, Distinctive Mutational Spectra Related to APOBEC-Catalyzed DNA Mutagenesis and Mutational Enrichment in Kinases Associated With Cell Migration and Invasion. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E360-E364.	1.8	86
92	Alternative Genetic Pathways in Parathyroid Tumorigenesis*. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3775-3780.	1.8	84
93	Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochemical and Biophysical Research Communications, 2006, 350, 17-24.	1.0	84
94	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. American Journal of Surgical Pathology, 2009, 33, 72-80.	2.1	84
95	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncology, The, 2016, 17, 1240-1247.	5.1	84
96	Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight, 2017, 2, e92061.	2.3	84
97	Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clinical Endocrinology, 2000, 53, 205-211.	1.2	83
98	The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 1717-1728.	3.2	83
99	Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine, 2016, 22, 464-471.	15.2	83
100	Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications. Clinical Cancer Research, 2007, 13, 161-169.	3.2	81
101	Evaluation of Retinoblastoma and Ki-67 Immunostaining as Diagnostic Markers of Benign and Malignant Parathyroid Disease. World Journal of Surgery, 1999, 23, 68-74.	0.8	80
102	Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients. Clinical Cancer Research, 2004, 10, 8204-8213.	3.2	80
103	Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Medicine, 2014, 6, 24.	3.6	75
104	Familial Isolated Hyperparathyroidism as a Variant of Multiple Endocrine Neoplasia Type 1 in a Large Danish Pedigree1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 165-167.	1.8	74
105	Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing. Cancer Research, 2011, 71, 29-39.	0.4	74
106	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Medicine, 2015, 7, 98.	3.6	74
107	Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Human Genetics, 1997, 99, 342-349.	1.8	72
108	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nature Communications, 2014, 5, 4361.	5.8	72

#	Article	IF	Citations
109	Classification of Renal Neoplasms Based on Molecular Signatures. Journal of Urology, 2006, 175, 2302-2306.	0.2	70
110	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	0.6	70
111	Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Human Cell, 2020, 33, 695-708.	1.2	69
112	Birt-Hogg-DubÃ© renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Medical Genomics, 2010, 3, 59.	0.7	68
113	Renal papillary adenomaâ€"a putative precursor of papillary renal cell carcinoma. Human Pathology, 2007, 38, 239-246.	1.1	67
114	An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases. Oral Oncology, 2015, 51, 355-362.	0.8	64
115	Mapping of the second locus for the Van der Woude syndrome to chromosome 1p34. European Journal of Human Genetics, 2001, 9, 747-752.	1.4	63
116	Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Research, 2002, 62, 6598-605.	0.4	63
117	MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases. Journal of Clinical Pathology, 2015, 68, 685-691.	1.0	62
118	Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clinical Endocrinology, 1999, 50, 191-196.	1.2	60
119	Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models. Cancer Research, 2009, 69, 8256-8264.	0.4	60
120	A Large Multiple Endocrine Neoplasia Type 1 Family with Clinical Expression Suggestive of Anticipation1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3487-3492.	1.8	59
121	Prognostic Value of Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. Clinical Cancer Research, 2009, 15, 650-659.	3.2	59
122	Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Modern Pathology, 2011, 24, 688-697.	2.9	59
123	Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response. PLoS Genetics, 2008, 4, e1000176.	1.5	58
124	Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. Journal of Clinical Investigation, 2020, 130, 5833-5846.	3.9	58
125	Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. PLoS Biology, 2018, 16, e2004285.	2.6	57
126	Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas. European Urology, 2015, 68, 77-83.	0.9	56

#	Article	IF	Citations
127	Familial non-VHL non-papillary clear-cell renal cancer. Lancet, The, 1997, 349, 848-849.	6.3	55
128	The phospholipase C Î²3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Human Molecular Genetics, 1994, 3, 1775-1781.	1.4	53
129	Expression of S-100 protein in renal cell neoplasms. Human Pathology, 2006, 37, 462-470.	1.1	53
130	Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. OncoImmunology, 2012, 1, 18-27.	2.1	53
131	Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery, 2008, 143, 630-640.	1.0	52
132	Radiosensitization by Inhibiting STAT1 in Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 73, 288-295.	0.4	52
133	Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma. Cancer Research, 2012, 72, 4361-4371.	0.4	52
134	Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas. Scientific Reports, 2017, 7, 10660.	1.6	52
135	p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. International Journal of Cancer, 2010, 126, 2353-2361.	2.3	51
136	Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Medical Genomics, 2010, 3, 58.	0.7	50
137	Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. Human Molecular Genetics, 2012, 21, 5268-5279.	1.4	50
138	Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. Oncogene, 2002, 21, 1117-1122.	2.6	49
139	Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis. Clinical Cancer Research, 2004, 10, 2368-2378.	3.2	49
140	SETD2histone modifier loss in aggressive GI stromal tumours. Gut, 2016, 65, 1960-1972.	6.1	49
141	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	3.9	49
142	The Succinated Proteome of FH-Mutant Tumours. Metabolites, 2014, 4, 640-654.	1.3	48
143	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	7.7	48
144	Malignant melanoma in patients with multiple endocrine neoplasia type 1 and involvement of theMEN1 gene in sporadic melanoma. International Journal of Cancer, 2000, 87, 463-467.	2.3	47

#	Article	IF	Citations
145	Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2004, 28, 1045-1050.	2.1	46
146	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomeraseâ€inhibiting therapy. BJU International, 2010, 106, 62-65.	1.3	46
147	Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncology, The, 2010, 11, 571-578.	5.1	46
148	Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. Scientific Reports, 2017, 7, 7342.	1.6	46
149	Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Research and Treatment, 2011, 129, 319-329.	1.1	45
150	Genetics of Opisthorchis viverrini-related cholangiocarcinoma. Current Opinion in Gastroenterology, 2015, 31, 258-263.	1.0	45
151	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. Cancer Discovery, 2015, 5, 1133-1136.	7.7	45
152	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer, 2013, 119, 313-324.	2.0	43
153	Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells. Molecular Cancer Therapeutics, 2013, 12, 2157-2166.	1.9	43
154	High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biology, 2015, 16, 32.	3.8	42
155	Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nature Communications, 2017, 8, 15866.	5.8	42
156	Gene Expression Profiling of Renal Cell Carcinoma: Fig. 1.. Clinical Cancer Research, 2004, 10, 6315S-6321S.	3.2	39
157	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	0.9	39
158	A meiotic recombination in a new isolated familial somatotropinoma kindred. European Journal of Endocrinology, 2004, 150, 643-648.	1.9	38
159	Innovations and Challenges in Renal Cancer. Clinical Cancer Research, 2004, 10, 6277S-6281S.	3.2	38
160	A germline mutation inPBRM1predisposes to renal cell carcinoma. Journal of Medical Genetics, 2015, 52, 426-430.	1.5	38
161	CDC73/HRPT2 CpG island hypermethylation and mutation of 5â€²-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	1.6	37
162	Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism. American Journal of Pathology, 2002, 161, 1299-1306.	1.9	36

#	Article	IF	Citations
163	Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma. Urology, 2010, 75, 1365-1370.e3.	0.5	36
164	Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. Gut, 2020, 69, 1039-1052.	6.1	36
165	VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2010, 2, 296-308.	0.0	36
166	Single base mutation in the hormone binding domain of the thyroid hormone receptor Î² gene in generalised thyroid hormone resistance demonstrated by single stranded conformation polymorphism analysis. Biochemical and Biophysical Research Communications, 1991, 178, 606-612.	1.0	35
167	Deregulation of E2-EPF Ubiquitin Carrier Protein in Papillary Renal Cell Carcinoma. American Journal of Pathology, 2011, 178, 853-860.	1.9	35
168	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Global Oncology, 2020, 6, 628-638.	0.8	35
169	Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13.. Clinical Endocrinology, 2000, 53, 85-92.	1.2	34
170	Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 233-244.	1.0	34
171	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	0.9	34
172	Digital phenotyping by consumer wearables identifies sleep-associated markers of cardiovascular disease risk and biological aging. Communications Biology, 2019, 2, 361.	2.0	34
173	Genomic characterisation of breast fibroepithelial lesions in an international cohort. Journal of Pathology, 2019, 249, 447-460.	2.1	33
174	CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. Journal of Clinical Pathology, 2015, 68, 200-205.	1.0	32
175	Construction of a 1.2-Mb Sequence-Ready Contig of Chromosome 11q13 Encompassing the Multiple Endocrine Neoplasia Type 1 (MEN1) Gene. Genomics, 1997, 44, 94-100.	1.3	31
176	Gene Expression Profiling of Renal Cell Carcinoma and Its Implications in Diagnosis, Prognosis, and Therapeutics. Advances in Cancer Research, 2003, 89, 157-181.	1.9	31
177	Combined Gene Expression Profiling and RNAi Screening in Clear Cell Renal Cell Carcinoma Identify PLK1 and Other Therapeutic Kinase Targets. Cancer Research, 2011, 71, 5225-5234.	0.4	31
178	The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA. Molecular Carcinogenesis, 2010, 49, 215-223.	1.3	30
179	Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e482-e491.	5.1	30
180	Over Expression of Insulin-Like Growth Factor Binding Protein 3 in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2008, 179, 445-449.	0.2	29

#	Article	IF	Citations
181	THE GENETIC BASIS OF BREAST CANCER AND ITS CLINICAL IMPLICATIONS. Australian and New Zealand Journal of Surgery, 1999, 69, 95-105.	0.2	28
182	Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Research and Treatment, 2012, 132, 143-151.	1.1	28
183	Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Letters, 2008, 272, 260-267.	3.2	27
184	Disruption of tubular Flcn expression as a mouse model for renal tumor induction. Kidney International, 2015, 88, 1057-1069.	2.6	27
185	Genetics and genomics of breast fibroadenomas. Journal of Clinical Pathology, 2018, 71, 381-387.	1.0	27
186	The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. International Journal of Oncology, 2012, 41, 2139-2149.	1.4	26
187	MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression. Journal of Clinical Pathology, 2016, 69, 858-865.	1.0	26
188	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Scientific Reports, 2016, 6, 19552.	1.6	26
189	Transcriptional analysis of immune genes in Epsteinâ€“Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21, 1064-1070.	2.7	25
190	MED12, TERT and RARA in fibroepithelial tumours of the breast. Journal of Clinical Pathology, 2020, 73, 51-56.	1.0	25
191	Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in theMEN1 gene. , 1999, 26, 35-39.		24
192	Effect of Sildenafil Citrate on an Orthotopic Prostate Cancer Growth and Metastasis Model. Journal of Urology, 2003, 170, 994-997.	0.2	24
193	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. Cancer, 2009, 115, 2247-2251.	2.0	24
194	Prospects for Vasculature Reorganization in Sentinel Lymph Nodes. Cell Cycle, 2007, 6, 514-517.	1.3	23
195	Expression and chromosomal localization of the Requiem gene. Mammalian Genome, 1998, 9, 660-665.	1.0	22
196	Genome-wide screening using array-CGH does not reveal microdeletions/microduplications in children with Kabuki syndrome. European Journal of Human Genetics, 2005, 13, 260-263.	1.4	22
197	Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. Journal of Medical Investigation, 2006, 53, 9-19.	0.2	21
198	Molecular targets on the horizon for kidney and urothelial cancer. Nature Reviews Clinical Oncology, 2013, 10, 557-570.	12.5	21

#	Article	IF	Citations
199	Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. British Journal of Cancer, 1990, 62, 253-254.	2.9	20
200	Multiple endocrine neoplasia type 1. Seminars in Cancer Biology, 2000, 10, 299-312.	4.3	20
201	Genetic Screening for MEN1 Mutations in Families Presenting with Familial Primary Hyperparathyroidism. World Journal of Surgery, 2002, 26, 907-913.	0.8	20
202	Nuclear Imaging of Met-Expressing Human and Canine Cancer Xenografts with Radiolabeled Monoclonal Antibodies (MetSeekTM). Clinical Cancer Research, 2005, 11, 7064s-7069s.	3.2	20
203	Glypican 3 overexpression in primary and metastatic Wilms tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 67-76.	1.4	20
204	A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. BMC Medical Genomics, 2019, 12, 142.	0.7	20
205	Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours. Breast Cancer Research and Treatment, 2019, 174, 365-373.	1.1	20
206	Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma. American Journal of Clinical Pathology, 2006, 126, 79-85.	0.4	20
207	First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biology, 2011, 12, R96.	13.9	19
208	FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomarker Insights, 2011, 6, BMI.S6487.	1.0	19
209	Targeting the IRAK1â€“S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Research, 2021, 81, 1413-1425.	0.4	19
210	Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Medicine, 2021, 13, 3.	3.6	19
211	Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing. Modern Pathology, 2021, 34, 1320-1332.	2.9	19
212	Overexpression of glutathione s-transferase alpha in clear cell renal cell carcinoma. American Journal of Clinical Pathology, 2005, 123, 421-9.	0.4	19
213	Clinical and genetic studies of Van der Woude syndrome in Sweden. Acta Odontologica Scandinavica, 1999, 57, 72-76.	0.9	18
214	The management of familial breast cancer. Breast, 2000, 9, 247-263.	0.9	18
215	Population genomics in South East Asia captures unexpectedly high carrier frequency for treatable inherited disorders. Genetics in Medicine, 2019, 21, 207-212.	1.1	18
216	Oculopharyngeal muscular dystrophy (OPMD)â€report and genetic studies of an Australian kindred. Clinical Genetics, 1997, 51, 52-55.	1.0	17

#	Article	IF	Citations
217	Implementation of genomics in medical practice to deliver precision medicine for an Asian population. Npj Genomic Medicine, 2019, 4, 12.	1.7	17
218	Genetic and clinical characterization of sporadic cystic parathyroid tumours. Clinical Endocrinology, 2002, 56, 261-269.	1.2	16
219	Gene expression profiling of mesoblastic nephroma and Wilms tumorsâ€"comparison and clinical implications. Urology, 2004, 64, 362-368.	0.5	15
220	Fanconi's Anemia in Adulthood: Chemoradiation-Induced Bone Marrow Failure and a Novel FANCA Mutation Identified by Targeted Deep Sequencing. Journal of Clinical Oncology, 2011, 29, e591-e594.	0.8	15
221	Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Canadian Urological Association Journal, 2012, 1, S21-7.	0.3	15
222	Human Folliculin Delays Cell Cycle Progression through Late S and G2/M-Phases: Effect of Phosphorylation and Tumor Associated Mutations. PLoS ONE, 2013, 8, e66775.	1.1	15
223	Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. Breast Cancer Research, 2018, 20, 22.	2.2	15
224	Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma. Scientific Reports, 2019, 9, 2552.	1.6	15
225	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. Journal of Dental Research, 2019, 98, 652-658.	2.5	14
226	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. Anticancer Research, 2015, 35, 6639-53.	0.5	14
227	Multiple endocrine neoplasia type 1 (MEN1) in two Asian families. Human Genetics, 1994, 94, 468-72.	1.8	13
228	A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology, 2017, 49, 786-789.	0.3	13
229	Morphologic and genetic heterogeneity in breast fibroepithelial lesionsâ€"a comprehensive mapping study. Modern Pathology, 2020, 33, 1732-1745.	2.9	13
230	Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression. Oncotarget, 2015, 6, 32761-32773.	0.8	13
231	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	3.9	12
232	Renal Cell Carcinoma Deep Sequencing: Recent Developments. Current Oncology Reports, 2012, 14, 240-248.	1.8	11
233	Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma. Cancer Investigation, 2015, 33, 378-386.	0.6	11
234	Molecular insights into paediatric breast fibroepithelial tumours. Histopathology, 2018, 73, 809-818.	1.6	11

#	Article	IF	Citations
235	Assessment of different strategies for scalable production and proliferation of human myoblasts. Cell Proliferation, 2019, 52, e12602.	2.4	11
236	An Optimised Protocol Harnessing Laser Capture Microdissection for Transcriptomic AnalysisÂon Matched Primary and Metastatic Colorectal Tumours. Scientific Reports, 2020, 10, 682.	1.6	11
237	Upper Tract Urothelial Carcinomas in Patients with Chronic Kidney Disease: Relationship with Diagnostic Challenge. BioMed Research International, 2014, 2014, 1-9.	0.9	10
238	Osteoblast-specific deletion of Hrpt2/Cdc73 results in high bone mass and increased bone turnover. Bone, 2017, 98, 68-78.	1.4	10
239	CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Letters, 2021, 521, 268-280.	3.2	10
240	Gene profiling suggests a common evolution of bladder cancer subtypes. BMC Medical Genomics, 2013, 6, 42.	0.7	9
241	Germline hemizygous deletion of CDKN2Aâ€“CDKN2B locus in a patient presenting with Liâ€“Fraumeni syndrome. Npj Genomic Medicine, 2016, 1, 16015.	1.7	9
242	Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. International Journal of Oncology, 2018, 53, 1455-1468.	1.4	9
243	Epigenomic Consequences of Coding and Noncoding Driver Mutations. Trends in Cancer, 2016, 2, 585-605.	3.8	8
244	Inhibition of placental growth factor in renal cell carcinoma. Anticancer Research, 2015, 35, 531-41.	0.5	8
245	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. International Journal of Cancer, 2007, 121, 992-998.	2.3	7
246	Defining the Molecular Alterations of Ampullary Carcinoma. Cancer Cell, 2016, 29, 135-136.	7.7	7
247	Genomics of worms, with an emphasis on Opisthorchis viverrini â€” opportunities for fundamental discovery and biomedical outcomes. Parasitology International, 2017, 66, 341-345.	0.6	7
248	The utility of a targeted gene mutation panel in refining the diagnosis of breast phyllodes tumours. Pathology, 2019, 51, 531-534.	0.3	7
249	Assessing Matched Normal and Tumor Pairs in Next-Generation Sequencing Studies. PLoS ONE, 2011, 6, e17810.	1.1	7
250	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. Cell Reports Medicine, 2022, 3, 100526.	3.3	7
251	A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. Cases Journal, 2009, 2, 7769.	0.4	6
252	Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. Journal of Medical Case Reports, 2010, 4, 36.	0.4	6

#	Article	IF	Citations
253	The importance of including diverse populations in cancer genomic and epigenomic studies. Nature Reviews Cancer, 2019, 19, 361-362.	12.8	6
254	NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	6
255	Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers. Cancers, 2022, 14, 576.	1.7	6
256	Breast cancer in six women with neurofibromatosis type 1. Breast, 1997, 6, 155-160.	0.9	5
257	Fine mapping of the MLK-3 gene within 11q13 and its exclusion as the MEN1 susceptibility gene. Human Genetics, 1997, 99, 776-780.	1.8	5
258	Characterization of a new SNP c767A/T (Arg222Trp) in the candidate TSG FUS2 on human chromosome 3p21.3: prevalence in Asian populations and analysis of association with nasopharyngeal cancer. Molecular and Cellular Probes, 2004, 18, 39-44.	0.9	5
259	Gene expression profiling of renal cell carcinoma and clinical implications. Urology, 2005, 65, 231-237.	0.5	5
260	Genetic and Epigenetic Alterations in Cancer. , 2020, , 209-224.e2.		5
261	Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma. Liver Cancer International, 2020, 1, 25-35.	0.2	5
262	Involvement of PBRM1 in VHL diseaseâ€'associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway. Oncology Letters, 2021, 22, 835.	0.8	5
263	Genetics of Multiple Endocrine Neoplasia Type 1. Annals of the New York Academy of Sciences, 1994, 733, 453-463.	1.8	4
264	Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. Npj Breast Cancer, 2022, 8, 44.	2.3	4
265	A genomicâ€augmented multivariate prognostic model for the survival of naturalâ€killer/Tâ€cell lymphoma patients from an international cohort. American Journal of Hematology, 2022, 97, 1159-1169.	2.0	4
266	Multiple Endocrine Neoplasia Type 1 and the Search for the Genetic Trigger. Hormone Research, 1997, 47, 179-184.	1.8	3
267	A comparison study reveals important features of agreement and disagreement between summarized DNA and RNA data obtained from renal cell carcinoma. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 657, 77-83.	0.9	3
268	Chronic Kidney Disease and Upper Tract Urothelial Carcinomas. BioMed Research International, 2014, 2014, 1-2.	0.9	3
269	Functional characterisation guides classification of novel BAP1 germline variants. Npj Genomic Medicine, 2020, 5, 50.	1.7	3
270	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. Journal of Clinical Neuroscience, 1997, 4, 176-180.	0.8	2

#	Article	IF	Citations
271	C306A single nucleotide polymorphism in the human CEBPD gene that maps at 8p11.1â€“p11.2. Molecular and Cellular Probes, 2001, 15, 395-397.	0.9	2
272	Gene Expression Profiling in Kidney Cancer: Combining Differential Expression and Chromosomal and Pathway Analyses. Clinical Genitourinary Cancer, 2006, 5, 227-231.	0.9	2
273	Misregulation of Histone Methylation Regulators in Cancer. Cancer Drug Discovery and Development, 2017, , 221-248.	0.2	2
274	Molecular Characterization of Renal Cell Carcinoma. , 2012, , 91-111.		2
275	Molecular Genetics of Familial Hyperparathyroidism. International Journal on Disability and Human Development, 2001, 2, .	0.2	1
276	Parathyroid tumorigenesis in association with primary hyperparathyroidism. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 51-60.	0.6	1
277	Gene expression profiling of endocrine tumors by microarray analysis. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 162-167.	0.6	1
278	Molecular Genetics of Renal Cell Carcinoma. , 2017, , 83-103.		1
279	Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. Journal of Cancer, 2019, 10, 5130-5138.	1.2	1
280	â€œSeed and Soilâ€•Theory of Metastasis. , 2011, , 3354-3355.		1
281	Generation of Non-Hodgkin Lymphoma Patient-Derived Xenografts and in Depth Characterization of a Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma Model. Blood, 2016, 128, 4128-4128.	0.6	1
282	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epsteinâ€“Barr virus positive gastric cancer.. Journal of Clinical Oncology, 2019, 37, e15509-e15509.	0.8	1
283	Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2012, 30, 368-368.	0.8	1
284	Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. American Journal of Cancer Research, 2017, 7, 484-502.	1.4	1
285	Paediatric <scp>BCOR</scp>â€associated sarcomas with a novel long spliced internal tandem duplication of <scp>BCOR</scp> exon 15. Journal of Pathology: Clinical Research, 2022, 8, 470-480.	1.3	1
286	HRPT2 and parathyroid cancer. Lancet Oncology, The, 2004, 5, 78.	5.1	0
287	Renal-cell carcinomas. , 0, , 579-583.		0
288	S13-3 Molecular sub-classification of renal cancer and new diagnostic markers. Japanese Journal of Urology, 2004, 95, 226.	0.0	0

#	Article	IF	Citations
289	An Integrated Oncogenomic Approach: From Genes to Pathway Analyses. , 2010, , 31-50.		0
290	Molecular Biology and Genetics. , 2013, , 19-37.		0
291	â€œSeed and Soilâ€•Theory of Metastasis. , 2015, , 1-2.		0
292	Tiefe molekulare Characterisierung des Cholangiokarzinoms. , 2017, 55, .		0